Safety and long-term immunogenicity of the two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in adults in Sierra Leone: a combined open-label, non-randomised stage 1, and a randomised, double-blind, controlled stage 2 trial

Posted on by

Lancet Infectious Diseases
Jan 2022 Volume 22 Number 1 p1-150, e1-e40
https://www.thelancet.com/journals/laninf/issue/current

 

Safety and long-term immunogenicity of the two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in adults in Sierra Leone: a combined open-label, non-randomised stage 1, and a randomised, double-blind, controlled stage 2 trial
David Ishola, et al. on behalf of the EBL3001 study group